Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib in Perioperative Hepatocellular Carcinoma
NCT04297202Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Major Pathologic Response at 6 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04297202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04297202.